CClinicalTrials.gg
CompletedNCT03367000Updated Dec 8, 2017

Protein Supplementation In Dialysis Patients

An interventional study of Ceprolac and Dietary counseling (DC) in Peritoneal Dialysis Patients, sponsored by National University of Malaysia. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-12-08.

Sponsored by National University of Malaysia · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The dialysis population has a strikingly high incidence of mortality. The life expectancy of chronic dialysis patients is 20 years less than that of the general population. Approximately 50% of individuals with end stage renal disease (ESRD) die from a cardiovascular (CV) cause with mortality being 15 to 30 times higher than the age-adjusted CV mortality in the general population. There is also a steady increase of patients with diabetes and the older age groups coming into dialysis. The treatment of patients with ESRD aims at prolonging life, achieving good nutritional status and promoting the best possible functioning and quality of life (QOL). Several factors that are beyond adequacy of dialysis predict high mortality in ESRD patients. Associated co-morbidities and malnutrition factors are independently associated and the combined presence of both malnutrition and co-morbidities manifest the worst survival.Therefore this study investigates the efficacy of protein supplementation in improving health status and quality of life among peritoneal dialysis (PD) patients. This research will also generate basic data about significant health markers critical to the health status of PD patients.

Read the detailed description

This study is a randomised, open labeled controlled trial where a total of 74 PD patients (37 supplemented; 37 control) were recruited from government and private settings. Subjects were randomised to either the intervention or control group. The intervention group received hydrolysed whey protein supplement and diet counselling for 6 months while the control group received only diet counselling for 6 months.

Patients who consented were first subjected to a screening for identification of eligible subjects. The screening involved basic anthropometry measures (height, weight, BMI), routine biochemistry result obtained from medical record, assessment of nutritional status and dietary evaluation. About 4ml of pre-dialysis blood was also collected by respective nurses for additional laboratory parameters (hsCRP).

During the 6 months of treatment period, patients in both control and intervention groups were assessed at baseline and end of the study (at 6 months) for anthropometry assessment, laboratory results, medical condition, hospitalisations, nutritional status, dietary intake and compliance towards supplementation (intervention group only).

02

Conditions studied

  • Peritoneal Dialysis Patients
03

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged > 18 years old and ≤70 years old
  • Undergone dialysis at least for 6 months.
  • Categorised as malnourished based on BMI \<24 kg/m² and serum albumin ≤40 g/L criteria
  • No incidence of hospitalisation for past 3 months, free of infection/sepsis and have not undergone surgery for past 6 months.

Exclusion criteria

Exclusion Criteria:

  • Patients with high inflammatory diseases, malignancy, cancer
  • Vegetarian patients
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Ceprolac

    Received supplementation which added 27.6g protein and 114kcal to daily nutritional intake as well as standard diet counselling for 6 months

    Dietary Supplement: Ceprolac

  • Placebo comparator
    Dietary counseling (DC)

    Received standard diet counselling only for 6 months.

    Other: Dietary counseling (DC)

Interventions

  • Dietary supplementCeprolac

    The supplement was packed into two \~15g sachets in powder form of a 90-94% whey protein isolate and hydrolysed whey. The protein powder was dissolved in 75-100ml water at room temperature and was ingested post meal once daily.

  • OtherDietary counseling (DC)

    Received standard dietary counseling at baseline and month 6.

05

What researchers measure

Primary outcomes

  1. Serum albumin

    Biochemistry marker that indicates nutritional status

    Time frame: Change from baseline serum albumin at 6 months of the study

  2. Body mass index (BMI)

    Index that depicts if one's current weight is ideal for their height

    Time frame: Change from BMI at 6 months of the study

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Mah JY, Choy SW, Roberts MA, Desai AM, Corken M, Gwini SM, McMahon LP. Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2020 May 11;5(5):CD012616. doi: 10.1002/14651858.CD012616.pub2. PubMed 32390133 ↗
  • Sahathevan S, Se CH, Ng S, Khor BH, Chinna K, Goh BL, Gafor HA, Bavanandan S, Ahmad G, Karupaiah T. Clinical efficacy and feasibility of whey protein isolates supplementation in malnourished peritoneal dialysis patients: A multicenter, parallel, open-label randomized controlled trial. Clin Nutr ESPEN. 2018 Jun;25:68-77. doi: 10.1016/j.clnesp.2018.04.002. PubMed 29779821 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03367000
Lead sponsor
National University of Malaysia
Responsible party
Tilakavati Karupaiah (Senior Lecturer, National University of Malaysia) — Principal investigator
First posted
Dec 8, 2017
Start date
Feb 1, 2012
Primary completion
Aug 31, 2013
Completion
Aug 31, 2013
Last update
Dec 8, 2017

Study contacts

Tilakavati Karupaiah
principal investigator · Senior Lecturer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion